Apertor Pharmaceuticals
Apertor Pharmaceuticals is dedicated to creating novel molecular glues for therapeutic applications in oncology, focusing on disrupting disease-causing protein-protein interactions through proximity induction with heterobifunctional drugs. Their innovative platform aims to develop transformative therapies for cancer patients, emphasizing precision medicine and targeted disruption of oncogenic signaling pathways.
Industries
Nr. of Employees
small (1-50)
Apertor Pharmaceuticals
San Francisco, California, United States, North America
Products
Preclinical heterobifunctional program targeting mTORC1/4E‑BP1
A discovery‑stage heterobifunctional program designed to disrupt mTORC1/4E‑BP1 protein–protein interactions in solid tumors via anchor‑protein recruitment.
Discovery programs addressing RAS‑pathway and other oncology targets
Multiple discovery programs using heterobifunctional constructs to address RAS‑pathway driven cancers (e.g., non‑small cell lung, pancreatic, colorectal) and additional undisclosed oncology targets.
Preclinical heterobifunctional program targeting mTORC1/4E‑BP1
A discovery‑stage heterobifunctional program designed to disrupt mTORC1/4E‑BP1 protein–protein interactions in solid tumors via anchor‑protein recruitment.
Discovery programs addressing RAS‑pathway and other oncology targets
Multiple discovery programs using heterobifunctional constructs to address RAS‑pathway driven cancers (e.g., non‑small cell lung, pancreatic, colorectal) and additional undisclosed oncology targets.
Services
Discovery collaborations and scientific partnerships
Collaborative engagements for discovery-stage science and pipeline partnerships focused on developing proximity‑inducing therapeutics for oncology targets.
Discovery collaborations and scientific partnerships
Collaborative engagements for discovery-stage science and pipeline partnerships focused on developing proximity‑inducing therapeutics for oncology targets.
Expertise Areas
- Proximity‑induced therapeutic design
- Heterobifunctional molecule development
- Medicinal chemistry and ADME optimization
- Computational structural modeling and linker design
Key Technologies
- Heterobifunctional proximity‑inducing molecules
- Anchor‑protein recruitment (FKBP12 anchoring)
- Rapamycin‑scaffold anchor ligands
- Computational modeling for ligand/linker design